Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.64 |
| ▸ | ITGAV | P06756 | 20/20 | 0.64 |
| ▸ | ITGB5 | P18084 | 5/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.54 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6371795 | 0.89 | ITGB3 (0.56) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL5746865 | 0.88 | ITGB3 (0.63) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL5736678 | 0.86 | ITGB3 (0.64) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL6426684 | 0.85 | ITGAV (0.55) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL5736210 | 0.84 | ITGB3 (0.59) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL5736700 | 0.84 | ITGB3 (0.65) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL5746940 | 0.83 | ITGB3 (0.51) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL5735483 | 0.81 | ITGB3 (0.63) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL2488319 | 0.78 | ITGB3 (1.00) | ITGB3ITGAVITGB5 | |
| SCHEMBL20139563 | 0.78 | ITGB3 (0.80) | ITGB3ITGAVITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390362-B1 | SUBSTITUTED BENZOFURANS AND BENZOTHIOPHENES, METHODS OF MAKING AND METHODS OF USE AS INTEGRIN ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2006-12-20 | — | — | EP | claimed |
| EP-1390362-A1 | SUBSTITUTED BENZOFURANS AND BENZOTHIOPHENES, METHODS OF MAKING AND METHODS OF USE AS INTEGRIN ANTAGONISTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2004-02-25 | — | — | EP | claimed |
| US-20030018064-A1 | Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-01-23 | — | — | US | claimed |
| WO-2002088118-A1 | SUBSTITUTED BENZOFURANS AND BENZOTHIOPHENES, METHODS OF MAKING AND METHODS OF USE AS INTEGRIN ANTAGONISTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-11-07 | — | — | WO | claimed |
| EP-1390362-B1 | SUBSTITUTED BENZOFURANS AND BENZOTHIOPHENES, METHODS OF MAKING AND METHODS OF USE AS INTEGRIN ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20050228011-A1 | Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-10-13 | — | — | US | disclosed |
| US-20050165036-A1 | Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-07-28 | — | — | US | disclosed |
| US-6872730-B2 | Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| EP-1390362-A1 | SUBSTITUTED BENZOFURANS AND BENZOTHIOPHENES, METHODS OF MAKING AND METHODS OF USE AS INTEGRIN ANTAGONISTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030018064-A1 | Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-01-23 | — | — | US | disclosed |
| WO-2002088118-A1 | SUBSTITUTED BENZOFURANS AND BENZOTHIOPHENES, METHODS OF MAKING AND METHODS OF USE AS INTEGRIN ANTAGONISTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165036-A1 | Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists | ITGB5, ITGAV, ITGB1 | ITGB3 4/4885ITGAV 2/4885ITGB5 1/4885 |
| US-20030018064-A1 | Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists | VCAM1, ITGB1, ITGB7 | ITGB3 7/4885ITGAV 6/4885ITGB5 5/4885 |
| US-20050228011-A1 | Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists | ITGB5, ITGAV, ITGB1 | ITGB3 4/4885ITGAV 2/4885ITGB5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.